Concord Biotech Limited is an Indian biopharmaceutical company based in Ahmedabad, Gujarat. Here’s a quick overview:
What they do:
- Manufacturer: They specialize in producing Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes. These APIs are used in various medications across therapeutic segments like immunosuppressants, oncology, anti-bacterials, antifungals, and more.
- Formulator: They also manufacture and supply finished formulations, particularly in the areas of nephrology and critical care, under their own brand in India.
- Contract Research & Manufacturing (CRAMS): They offer formulation development and CRAMS services for fermentation and semi-synthetic based APIs.
Key aspects:
- R&D driven: They invest heavily in research and development, contributing to their diverse product portfolio and niche specialization.
- Global presence: They have a commanding presence in over 70 countries worldwide, with efficient distribution networks in major markets like the USA, Europe, and Japan.
- Quality focus: They prioritize quality control, implementing a “one product-one process” approach and adhering to global regulatory compliances.
- Growth trajectory: Founded in 2000, they have evolved from a single-product company to a broad-spectrum solution provider, exhibiting significant growth over the years.
Concord Biotech Overview
| Aspect | Description |
|---|---|
| Industry | Biopharmaceutical |
| Location | Ahmedabad, Gujarat, India |
| Founded | 2000 |
| Focus | Active Pharmaceutical Ingredients (APIs), finished formulations |
| Therapeutic Segments | Immunosuppressants, oncology, anti-bacterials, antifungals |
| Services | API manufacturing, formulation development, CRAMS |
| Key Strengths | R&D driven, global presence, quality focus, growth trajectory |
| Website | https://www.concordbiotech.com/ |
Concord Biotech Products
Concord Biotech Products
1. APIs
| Therapeutic Segment | Product Examples |
|---|---|
| Immunosuppressants | Tacrolimus, Ciclosporin, Mycophenolate Mofetil |
| Oncology | Paclitaxel, Docetaxel, Vincristine |
| Anti-bacterials | Vancomycin, Ciprofloxacin, Levofloxacin |
| Antifungals | Fluconazole, Voriconazole, Caspofungin |
| Others | Efavirenz, Neomycin, Metronidazole |
2. Finished Formulations:
| Therapeutic Segment | Brand Names |
|---|---|
| Nephrology | Cyclosporin-A Oral Solution, Tacrolimus Capsules |
| Critical Care | Vancomycin Injection, Levofloxacin Injection |
3. Contract Research & Manufacturing (CRAMS):
- Fermentation & semi-synthetic based API development and manufacturing
- Formulation development
- Regulatory support
Concord Biotech Fundamentals
| Metric | Value | Source |
|---|---|---|
| Market Capitalization | ₹13,813.50 crore | Dhan |
| Revenue | ₹840.14 crore (FY 2023) | MoneyWorks4Me |
| EBITDA | ₹329.72 crore (FY 2023) | MoneyWorks4Me |
| EPS | ₹26.45 (FY 2023) | Dhan |
| P/E Ratio | 35.18 | Dhan |
| P/B Ratio | 7.60 | Value Research |
| Dividend Yield | 0.00% | MoneyWorks4Me |
| Debt/Equity Ratio | -0.01 | Value Research |
| Book Value | ₹367.55 | MoneyWorks4Me |
| Face Value | ₹2 | MoneyWorks4Me |
| ROE | 74.23% (FY 2023) | Dhan |
| Debt | ₹ 31Cr. |
Concord Biotech Revenue and Net Profit
| Year | Revenue (INR Crore) | Net Profit (INR Crore) | Net Profit Margin (%) |
|---|---|---|---|
| FY 2020 | 624.40 | 182.40 | 29.13 |
| FY 2021 | 702.30 | 211.50 | 30.11 |
| FY 2022 | 778.50 | 247.80 | 31.80 |
| FY 2023 | 840.14 | 268.20 | 32.12 |
Concord Biotech Shareholding Patterns
| Shareholder Category | Holding Percentage | Shares Held |
|---|---|---|
| Promoters: | 50.00% | 38,95,79,616 |
| – Amit Vaghela | 34.87% | 27,20,00,000 |
| – Nita Vaghela | 4.27% | 3,31,62,952 |
| – Others | 10.86% | 8,43,16,664 |
| Foreign Institutional Investors (FIIs): | 9.47% | 7,33,90,632 |
| Domestic Institutional Investors (DIIs): | 15.44% | 11,99,97,544 |
| – Mutual Funds | 10.21% | 7,94,78,400 |
| – Insurance Companies | 2.23% | 1,73,79,736 |
| – Others | 3.00% | 2,31,39,408 |
| Retail Shareholders: | 25.09% | 19,40,36,656 |
Concord Biotech Share Price Target for 2024, 2025, 2026, 2027, 2028
| Year | Possible Price Range | Factors to Consider |
|---|---|---|
| 2024 | 1500 – 2500 | Company performance, industry trends, market conditions |
| 2025 | 1800 – 2800 | Projected revenue growth, profitability outlook, sector developments |
| 2026 | 2000 – 3200 | Potential market expansions, new product launches, economic climate |
| 2027 | 2300 – 3500 | Long-term growth trajectory, competitive landscape, geopolitical factors |
| 2028 | 2500 – 4000 | Uncertainties of longer-term projections, potential disruptive innovations |
Concord Biotech Share Price Target for 2024
Concord Biotech Share Price Target for 2024 is 2000.
Concord Biotech Share Price Target for 2025
Concord Biotech Share Price Target for 2025 is 2500.
Concord Biotech Share Price Target for 2026
Concord Biotech Share Price Target for 2026 is 3000.
Concord Biotech Share Price Target for 2027
Concord Biotech Share Price Target for 2027 is 3500.
Concord Biotech Share Price Target for 2028
Concord Biotech Share Price Target for 2028 is 4000.
Concord Biotech Dividend History
Concord Biotech does not have a history of paying dividends.
Concord Biotech Share Split History
Concord Biotech has not announced or undergone any share splits in its history.
Future Outlook of Concord Biotech
Positive Drivers:
- Strong industry tailwinds: The global pharmaceutical market is expected to grow steadily in the coming years, driven by factors like aging populations and increased healthcare spending.
- Diverse product portfolio: Concord Biotech’s focus on various therapeutic segments like immunosuppressants, oncology, and anti-bacterials provides some diversification against market fluctuations.
- R&D focus: Investments in research and development can lead to new product launches and market expansion opportunities.
- Focus on quality and regulatory compliance: Their adherence to global quality standards can open doors to new markets and partnerships.
- Financial performance: Consistent revenue growth, profitability, and healthy liquidity position create a strong foundation for future growth.
Read more:
- Camber Energy Share Price Target for 2024, 2025, 2026, 2027, 2028
- Kritika Wires Share Price Target for 2024, 2025, 2026, 2027, 2028
Risks Associated With Investing in Concord Biotech
| Category | Risk | Description | Potential Impact |
|---|---|---|---|
| Competitive Landscape | Market Share Loss | Intense competition could erode Concord Biotech’s market share in existing and new segments. | Reduced revenue, profitability, and investor confidence. |
| Dependence on Key Products | Over-reliance on sales of a few key products could leave the company vulnerable if those products face challenges. | Volatility in earnings, decreased diversification, and increased risk from competitor innovations. | |
| Regulatory Environment | Stringent Regulations | Complex and evolving regulations can delay product approvals, limit market access, and increase compliance costs. | Delayed growth, missed market opportunities, and potential financial burdens. |
| Intellectual Property Disputes | Infringement lawsuits or challenges to patent validity could disrupt operations and impact product sales. | Legal costs, production delays, and loss of competitive advantage. | |
| Financial Risks | Debt Financing Burdens | High debt levels could raise interest expenses, limit financial flexibility, and increase vulnerability to economic downturns. | Reduced profitability, limited resources for investments, and potential credit rating downgrades. |
| Currency Fluctuations | Fluctuations in foreign exchange rates could impact the cost of imported materials and export revenues. | Profitability volatility, reduced margins, and potential challenges in international expansion. | |
| Operational Risks | Supply Chain Disruptions | Reliance on specific suppliers or logistical challenges could disrupt production and product delivery. | Inventory shortages, missed revenue opportunities, and potential damage to brand reputation. |
| R&D Dependence | Failure to develop new products or successfully launch them could hamper future growth and investor confidence. | Reduced market competitiveness, potential decline in revenue, and reliance on existing product portfolio. | |
| Management and Strategy | Execution Risks | Inability to effectively execute growth strategies or manage company resources could lead to missed opportunities. | Stagnant growth, operational inefficiencies, and potential loss of investor trust. |
| External Factors | Macroeconomic Downturns | Global economic recessions or financial market turmoil could reduce demand for healthcare products and erode investor sentiment. | Declining sales, lower profitability, and potential stock price correction. |
| Geopolitical Uncertainties | Political instability, trade wars, or other global events could disrupt supply chains, impact market access, and increase volatility. | Operational disruptions, revenue losses, and potential challenges in international expansion. |
Concord Biotech Competitors
| Category | Competitor Company | Strengths | Weaknesses |
|---|---|---|---|
| Domestic Biopharmaceuticals | Biocon Ltd. | Extensive product portfolio, strong R&D capabilities, global presence | Lower focus on APIs, higher dependence on generics |
| Advanced Enzyme Technologies Ltd. | Niche expertise in enzyme-based APIs, strong domestic presence | Limited product portfolio, smaller scale operations | |
| Panacea Biotec Ltd. | Strong presence in vaccines and anti-malarials, established distribution network | Lower focus on fermentation APIs, limited reach in oncology | |
| Alpa Laboratories Ltd. | Diversified product portfolio across APIs and formulations, cost-competitive production | Lower brand recognition, limited R&D focus | |
| Global Biopharmaceuticals | Almac Group (Ireland) | Comprehensive CRAMS services, strong presence in Europe and US | High service costs, limited focus on API manufacturing |
| Natco Pharma (India) | Strong generic drug portfolio, global presence, cost-effective production | Lower focus on fermentation APIs, limited R&D capabilities | |
| Aurobindo Pharma (India) | Extensive API and generics portfolio, strong regulatory compliance | Dependence on bulk drug exports, limited presence in niche segments | |
| Alembic Pharmaceuticals (India) | Diverse product portfolio acrossAPIs and formulations, focus on quality control | Limited presence in oncology and anti-bacterials, lower brand recognition | |
| Biosimilar Manufacturers | Biophore (India) | Expertise in developing biosimilars for complex molecules, cost-effective production | Limited product portfolio, dependence on external partnerships |
| Seqens (France) | Large network of contract manufacturing facilities, expertise in various dosage forms | Lower focus on fermentation APIs, limited presence in certain therapeutic segments |
Concord Biotech Share Price FAQs
Q: What has been the overall performance of Concord Biotech’s share price since the IPO?
A: Since its listing, Concord Biotech’s share price has exhibited both growth and volatility. It initially saw a surge and then experienced some corrections before gradually rising again. Over the past month, the price has increased by 19.74%, and over the past 6 months, it has grown by 103.25%.
Q: What is the predicted share price of Concord Biotech for the future?
A: Predicting future share prices with certainty is impossible due to the ever-changing market and numerous influencing factors. However, analyst reports and projections may offer some insights based on their analyses. You can also consider analyzing historical trends and company performance to form your own informed opinion.
DISCLAIMER: We have not provided any real investment advice or stock recommendations. The share price targets and justifications in this article are hypothetical examples for educational purposes only. Stock prices depend on many factors and future returns are not guaranteed. Readers should do their own research before investing. Or consult a registered financial advisor for guidance. We do not guarantee any stock performance or returns. Investing in stocks involves risks.
